• negative regulation of neuron apoptotic process • negative regulation of norepinephrine uptake • response to interleukin-1 • response to interferon-gamma • regulation of glutamate secretion • response to magnesium ion • synaptic transmission, dopaminergic • regulation of reactive oxygen species biosynthetic process • positive regulation of protein serine/threonine kinase activity • cellular response to epinephrine stimulus • positive regulation of synaptic transmission • cellular response to copper ion • regulation of synaptic vesicle recycling • activation of cysteine-type endopeptidase activity involved in apoptotic process • response to cocaine • positive regulation of glutathione peroxidase activity • negative regulation of platelet-derived growth factor receptor signaling pathway • negative regulation of serotonin uptake • regulation of dopamine secretion • regulation of long-term neuronal synaptic plasticity • response to iron(II) ion • behavioral response to cocaine • 運動の調節 • adult locomotory behavior • positive regulation of neurotransmitter secretion • cellular response to fibroblast growth factor stimulus • positive regulation of peptidyl-serine phosphorylation • regulation of acyl-CoA biosynthetic process • positive regulation of endocytosis • synaptic vesicle endocytosis • 興奮性シナプス後電位 • regulation of neuronal synaptic plasticity • mitochondrial membrane organization • negative regulation of mitochondrial electron transport, NADH to ubiquinone • 化学的シナプス伝達 • negative regulation of protein phosphorylation • negative regulation of exocytosis • positive regulation of hydrogen peroxide catabolic process • negative regulation of microtubule polymerization • calcium ion homeostasis • mitochondrial ATP synthesis coupled electron transport • positive regulation of inositol phosphate biosynthetic process • dopamine biosynthetic process • synapse organization • negative regulation of dopamine metabolic process • positive regulation of release of sequestered calcium ion into cytosol • negative regulation of apoptotic process • regulation of reactive oxygen species metabolic process • regulation of neurotransmitter secretion • negative regulation of dopamine uptake involved in synaptic transmission • negative regulation of transcription from RNA polymerase II promoter • microglial cell activation • dopamine uptake involved in synaptic transmission • response to lipopolysaccharide • protein destabilization • neutral lipid metabolic process • negative regulation of thrombin-activated receptor signaling pathway • membrane organization • negative regulation of transporter activity • cellular protein metabolic process • negative regulation of cysteine-type endopeptidase activity involved in apoptotic process • regulation of phospholipase activity • negative regulation of chaperone-mediated autophagy • 老化 • receptor internalization • negative regulation of monooxygenase activity • fatty acid metabolic process • dopamine metabolic process • regulation of neuron death • positive regulation of apoptotic process • synaptic vesicle transport • cellular response to oxidative stress • phospholipid metabolic process • negative regulation of histone acetylation • oxidation-reduction process • response to drug • regulation of macrophage activation • positive regulation of receptor recycling • long-term synaptic potentiation • アポトーシス • supramolecular fiber organization • regulation of presynapse assembly • positive regulation of inflammatory response • positive regulation of neuron death • negative regulation of neuron death • response to desipramine • regulation of transmembrane transporter activity • regulation of norepinephrine uptake • synaptic vesicle exocytosis • SNARE complex assembly • positive regulation of exocytosis • protein oligomerization • protein tetramerization • synaptic vesicle priming
^ abcGRCh38: Ensembl release 89: ENSG00000145335 - Ensembl, May 2017
^ abcGRCm38: Ensembl release 89: ENSMUSG00000025889 - Ensembl, May 2017
^"Human PubMed Reference:".
^"Mouse PubMed Reference:".
^ abUéda K, Fukushima H, Masliah E, Xia Y, Iwai A, Yoshimoto M, Otero DA, Kondo J, Ihara Y, Saitoh T (December 1993). “Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease”. Proc. Natl. Acad. Sci. U.S.A.90 (23): 11282?6. doi:10.1073/pnas.90.23.11282. PMC: 47966. PMID 8248242. http://www.pnas.org/content/90/23/11282.
^Xia Y, Saitoh T, Uéda K, Tanaka S, Chen X, Hashimoto M, Hsu L, Conrad C, Sundsmo M, Yoshimoto M, Thal L, Katzman R, Masliah E (October 2001). “Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms”. J. Alzheimers Dis.3 (5): 485?494. PMID 12214035. http://iospress.metapress.com/content/jpmvj4dubjpm3b73/.
^Xia Y, Saitoh T, Uéda K, Tanaka S, Chen X, Hashimoto M, Hsu L, Conrad C, Sundsmo M, Yoshimoto M, Thal L, Katzman R, Masliah E (2002). “Characterization of the human alpha-synuclein gene: Genomic structure, transcription start site, promoter region and polymorphisms: Erratum p489 Fig 3”. J. Alzheimers Dis.4 (4): 337. http://iospress.metapress.com/content/jpmvj4dubjpm3b73/.
^ abAlim MA, Hossain MS, Arima K, Takeda K, Izumiyama Y, Nakamura M, Kaji H, Shinoda T, Hisanaga S, Ueda K. (Jan 2002). “Tubulin seeds alpha-synuclein fibril formation.”. J. Biol. Chem.277 (3): 2112?7. doi:10.1074/jbc.M102981200. PMID 11698390.
^ abcBeyer K (September 2006). “Alpha-synuclein structure, posttranslational modification and alternative splicing as aggregation enhancers”. Acta Neuropathol.112 (3): 237?51. doi:10.1007/s00401-006-0104-6. PMID 16845533.
^Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T (February 1995). “The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system”. Neuron14 (2): 467?75. doi:10.1016/0896-6273(95)90302-X. PMID 7857654.
^Mori, F; Tanji, K; Yoshimoto, M; Takahashi, H; Wakabayashi, K (Jul 2002). “Demonstration of alpha-synuclein immunoreactivity in neuronal and glial cytoplasm in normal human brain tissue using proteinase K and formic acid pretreatment”. Exp Neurol176 (1): 98-104. PMID 12093086.
^Hoek KS, Schlegel NC, Eichhoff OM, Widmer DS, Praetorius C, Einarsson SO, Valgeirsdottir S, Bergsteinsdottir K, Schepsky A, Dummer R, Steingrimsson E (2008). “Novel MITF targets identified using a two-step DNA microarray strategy” (full text). Pigment Cell Melanoma Res.21 (6): 665?76. doi:10.1111/j.1755-148X.2008.00505.x. PMID 19067971. http://onlinelibrary.wiley.com/doi/10.1111/j.1755-148X.2008.00505.x/full#ss3.
^Yu S, Li X, Liu G, Han J, Zhang C, Li Y, Xu S, Liu C, Gao Y, Yang H, Uéda K, Chan P (March 2007). “Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody”. Neuroscience145 (2): 539?55. doi:10.1016/j.neuroscience.2006.12.028. PMID 17275196.
^McLean PJ, Kawamata H, Ribich S, Hyman BT (March 2000). “Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations”. J. Biol. Chem.275 (12): 8812?6. doi:10.1074/jbc.275.12.8812. PMID 10722726. http://www.jbc.org/content/275/12/8812.full.
^Davidson WS, Jonas A, Clayton DF, George JM (Apr 1998). “Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes” (free full text). J Biol Chem273 (16): 9443-9449. doi:10.1074/jbc.273.16.9443. PMID 9545270. http://www.jbc.org/content/273/16/9443.full.
^Lee HJ, Choi C, Lee SJ (January 2002). “Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form”. J. Biol. Chem.277 (1): 671?8. doi:10.1074/jbc.M107045200. PMID 11679584. http://www.jbc.org/content/277/1/671.full.
^Zhang L, Zhang C, Zhu Y, Cai Q, Chan P, Uéda K, Yu S, Yang H (December 2008). “Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody”. Brain Res1244: 40?52. doi:10.1016/j.brainres.2008.08.067. PMID 18817762.
^ abLiu G, Zhang C, Yin J, Li X, Cheng F, Li Y, Yang H, Uéda K, Chan P, Yu S (May 2009). “Alpha-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity”. Neurosci. Lett.454 (3): 187?92. doi:10.1016/j.neulet.2009.02.056. PMID 19429081.
^Uéda K, Saitoh T, Mori H (December 1994). “Tissue-dependent alternative splicing of mRNA for NACP, the precursor of non-A beta component of Alzheimer's disease amyloid.”. Biochem. Biophys. Res. Commun.205 (2): 1366?72. doi:10.1006/bbrc.1994.2816. PMID 7802671.
^George JM, Jin H, Woods WS, Clayton DF (August 1995). “Characterization of a novel protein regulated during the critical period for song learning in the zebra finch”. Neuron15 (2): 361?72. doi:10.1016/0896-6273(95)90040-3. PMID 7646890.
^Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, Asada A, Saito T, Kaji H, Yoshii M, Hisanaga S, Ueda K (August 2004). “Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein”. J. Alzheimers Dis.6 (4): 435?42; discussion 443?9. PMID 15345814.
^Bonini NM, Giasson BI (November 2005). “Snaring the function of alpha-synuclein”. Cell123 (3): 359?61. doi:10.1016/j.cell.2005.10.017. PMID 16269324.
^Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC (November 2005). “Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration”. Cell123 (3): 383?96. doi:10.1016/j.cell.2005.09.028. PMID 16269331.
^Burré J, Sharma M, Tsetsenis T, Buchman V, Etherton MR, Sudhof TC (September 2010). “Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro” (free full text). Science329 (5999): 1663?7. doi:10.1126/science.1195227. PMID 20798282. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235365/.
^A. A. Cooper, A. D. Gitler, A. Cashikar, C. M. Haynes, K. J. Hill, B. Bhullar,K. Liu, K. Xu, K. E. Strathearn, F. Liu, S. Cao, K. A. Caldwell, G. A.Caldwell, G. Marsischky, R. D. Kolodner, J. Labaer, J. C. Rochet, N. M.Bonini, and S. Lindquist. (2006). “Alpha-synuclein blocks ER-golgi traffic and Rab1 rescues neuron loss in Parkinson’s models”. Science313 (5785): 324?328. doi:10.1126/science.1129462. PMC: 1983366. PMID 16794039. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1983366/.
^Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ (December 2003). “Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein”. Science302 (5651): 1769?72. doi:10.1126/science.1090389. PMID 14657499.
^ abUversky VN (October 2007). “Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation”. J. Neurochem.103 (1): 17?37. doi:10.1111/j.1471-4159.2007.04764.x. PMID 17623039.
^Jao CC, Hegde BG, Chen J, Haworth IS, Langen R (December 2008). “Structure of membrane-bound alpha-synuclein from site-directed spin labeling and computational refinement”. Proc. Natl. Acad. Sci. U.S.A.105 (50): 19666?71. doi:10.1073/pnas.0807826105. PMC: 2605001. PMID 19066219. http://www.ncbi.nlm.nih.gov/pubmed/19066219?dopt=Abstract.
^Zhu M, Li J, Fink AL (October 2003). “The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation”. J. Biol. Chem.278 (41): 40186?97. doi:10.1074/jbc.M305326200. PMID 12885775.
^Madine J, Doig AJ, Middleton DA (May 2006). “A study of the regional effects of alpha-synuclein on the organization and stability of phospholipid bilayers”. Biochemistry45 (18): 5783?92. doi:10.1021/bi052151q. PMID 16669622.
^Varkey J, Isas JM, Mizuno N, Jensen MB, Bhatia VK, Jao CC, Petrlova J, Voss J, Stamou D, Steven AC, Langen R (August 2010). “Membrane curvature induction and tubulation is a common feature of synucleins and apolipoproteins”. J Biol Chem285 (42): 32486?93. doi:10.1074/jbc.M110.139576. PMC: 2952250. PMID 20693280. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2952250/.
^Zhu M, Qin ZJ, Hu D, Munishkina LA, Fink AL (July 2006). “Alpha-synuclein can function as an antioxidant preventing oxidation of unsaturated lipid in vesicles”. Biochemistry45 (26): 8135?42. doi:10.1021/bi052584t. PMID 16800638.
^Clayton D.F. and George J.M. (1998). “The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease”. Trends in Neuroscience21 (6): 249?254. doi:10.1016/S0166-2236(97)01213-7.
^Negro, A; Brunati, AM; Donella-Deana, A; Massimino, ML; Pinna, LA (Feb 2002). “Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation” (free full text). FASEB J16 (2): 210-212. doi:10.1096/fj.01-0517fje. PMID 11744621. http://www.fasebj.org/content/early/2002/02/02/fj.01-0517fje.long.
^Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L, Kahle PJ, Haass C (Jan 2000). “Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein” (free full text). J Biol Chem275 (1): 390-397. doi:10.1074/jbc.275.1.390. PMID 10617630. http://www.jbc.org/content/275/1/390.full.
^Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL (Feb 2001). “α-Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases” (free full text). J Biol Chem276 (6): 3879-3884. doi:10.1074/jbc.M010316200. PMID 11078745. http://www.jbc.org/content/276/6/3879.full.
^ abVlad C, Lindner K, Karreman C, Schildknecht S, Leist M, Tomczyk N, Rontree J, Langridge J, Danzer K, Ciossek T, Petre A, Gross ML, Hengerer B, Przybylski M (December 2011). “Autoproteolytic fragments are intermediates in the oligomerization/aggregation of the Parkinson's disease protein alpha-synuclein as revealed by ion mobility mass spectrometry”. Chembiochem12 (18): 2740?4. doi:10.1002/cbic.201100569. PMC: 3461308. PMID 22162214. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3461308/.
^Bartels T, Choi JG, Selkoe DJ (August 2011). “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation”. Nature477 (7362). doi:10.1038/nature10324. PMID 21841800. Lay summary – Harvard Medical School New Focus.
^Arima K, Uéda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (October 1998). “Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies”. Brain Res.808 (1): 93?100. doi:10.1016/S0006-8993(98)00734-3. PMID 9795161.
^Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (November 1998). “NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy”. Acta Neuropathol.96 (5): 439?44. doi:10.1007/s004010050917. PMID 9829806.
^Arima K, Hirai S, Sunohara N, Aoto K, Izumiyama Y, Uéda K, Ikeda K, Kawai M (October 1999). “Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in Lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies”. Brain Res.843 (1): 53?61. doi:10.1016/S0006-8993(99)01848-X. PMID 10528110.
^Arima K, Mizutani T, Alim MA, Tonozuka-Uehara H, Izumiyama Y, Hirai S, Ueda K (August 2000). “NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies”. Acta Neuropathol.100 (2): 115?21. doi:10.1007/s004010050002. PMID 10963357.
^Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Uéda K, Checler F, Kuroda S (December 2002). “NACP/alpha-synuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases”. Acta Neuropathol.104 (6): 637?48. doi:10.1007/s00401-002-0596-7. PMID 12410385.
^Kim HY, Heise H, Fernandez CO, Baldus M, Zweckstetter M (September 2007). “Correlation of amyloid fibril beta-structure with the unfolded state of alpha-synuclein”. Chembiochem8 (14): 1671?4. doi:10.1002/cbic.200700366. PMID 17722123.
^Sandal M, Valle F, Tessari I, Mammi S, Bergantino E, Musiani F, Brucale M, Bubacco L, Samori B (January 2008). “Conformational equilibria in monomeric α-synuclein at the single-molecule level”. PLoS Biol.6 (1): e6. doi:10.1371/journal.pbio.0060006. PMC: 2174973. PMID 18198943. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2174973/.
^Morshedi D, Aliakbari F, (Spring 2012). “The Inhibitory Effects of Cuminaldehyde on Amyloid Fibrillation and Cytotoxicity of Alpha-synuclein”. modares journal of medical sciences: pathobiology15 (1): 45-60. http://mjms.journals.modares.ac.ir/?_action=article&au=1238&_au=Farhang++Aliakbari.
^Woulfe J, Hoogendoorn H, Tarnopolsky M, Muñoz DG. (Nov14). “Monoclonal antibodies against Epstein-Barr virus cross-react with alpha-synuclein in human brain.”. Neurology55 (9): 1398-1401. PMID 11087792.
^“Mutation in the alpha-synuclein gene identified in families with Parkinson's disease”. Science276 (5321): 2045?7. (1997). doi:10.1126/science.276.5321.2045. PMID 9197268.
^Li J, Uversky VN, Fink AL (September 2001). “Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein”. Biochemistry40 (38): 11604?13. doi:10.1021/bi010616g. PMID 11560511.
^Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atarés B, Llorens V, Gomez Tortosa E, del Ser T, Muñoz DG, de Yebenes JG (February 2004). “The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia”. Ann. Neurol.55 (2): 164?73. doi:10.1002/ana.10795. PMID 14755719.
^Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K (October 2003). “alpha-Synuclein locus triplication causes Parkinson's disease”. Science302 (5646): 841. doi:10.1126/science.1090278. PMID 14593171.
^Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (Feb 2002). “alpha-Synuclein is phosphorylated in synucleinopathy lesions”. Nat Cell Biol4 (2): 160-164. PMID 11813001.
^Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E (March 2000). “C-terminal alpha-synuclein immunoreactivity in structures other than Lewy bodies in neurodegenerative disorders”. Acta Neuropathol.99 (3): 296?304. doi:10.1007/PL00007441. PMID 10663973.
^Wersinger C, Sidhu A (April 2003). “Attenuation of dopamine transporter activity by alpha-synuclein”. Neurosci. Lett.340 (3): 189?92. doi:10.1016/S0304-3940(03)00097-1. PMID 12672538.
^Lee FJ, Liu F, Pristupa ZB, Niznik HB (April 2001). “Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis”. FASEB J.15 (6): 916?26. doi:10.1096/fj.00-0334com. PMID 11292651.
^Choi P, Golts N, Snyder H, Chong M, Petrucelli L, Hardy J, Sparkman D, Cochran E, Lee JM, Wolozin B (September 2001). “Co-association of parkin and alpha-synuclein”. NeuroReport12 (13): 2839?43. PMID 11588587.
^Kawahara K, Hashimoto M, Bar-On P, Ho GJ, Crews L, Mizuno H, Rockenstein E, Imam SZ, Masliah E (March 2008). “alpha-Synuclein aggregates interfere with Parkin solubility and distribution: role in the pathogenesis of Parkinson disease”. J. Biol. Chem.283 (11): 6979?87. doi:10.1074/jbc.M710418200. PMID 18195004.
^Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, Wolozin B, Chang JS, Lee YH, Kwon TK, Chung KC, Yoon SH, Hahn SJ, Kim MS, Jo YH, Min DS (April 2002). “alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells”. J. Biol. Chem.277 (14): 12334?42. doi:10.1074/jbc.M110414200. PMID 11821392.
^Neystat M, Rzhetskaya M, Kholodilov N, Burke RE (June 2002). “Analysis of synphilin-1 and synuclein interactions by yeast two-hybrid beta-galactosidase liquid assay”. Neurosci. Lett.325 (2): 119?23. doi:10.1016/S0304-3940(02)00253-7. PMID 12044636.
^Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C, Pleasure D (December 1991). “Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin”. Cancer Res.51 (24): 6529?38. PMID 1742726.
^Kawamata H, McLean PJ, Sharma N, Hyman BT (May 2001). “Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations”. J. Neurochem.77 (3): 929?34. doi:10.1046/j.1471-4159.2001.00301.x. PMID 11331421.
^Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA (May 1999). “Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions”. Nat. Genet.22 (1): 110?4. doi:10.1038/8820. PMID 10319874.
^Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, Jakes R (September 1999). “alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356”. J. Biol. Chem.274 (36): 25481?9. doi:10.1074/jbc.274.36.25481. PMID 10464279.
^Giasson BI, Lee VM, Trojanowski JQ (2003). “Interactions of amyloidogenic proteins”. Neuromolecular Med.4 (1-2): 49?58. doi:10.1385/NMM:4:1-2:49. PMID 14528052.
^Ono, Kenjiro; Takahashi, Ryoichi; Ikedia, Tokuhei; Yamada, Masahito (2012). “Cross-seeding effects of amyloid β-protein and α-synuclein”. Journal of Neurochemistry122 (5): 883-90. doi:10.1111/j.1471-4159.2012.07847.x. PMID 22734715. http://www.ncbi.nlm.nih.gov/pubmed/?term=Cross-seeding+effects+of+amyloid+β-protein+and+α-synuclein2013年2月13日閲覧。.
…alpha-synuclein, a 140 amino acid presynaptic protein found mutated in rare families with PD. Lewy bodies also contain synphilin-1 and other cytoskeletal proteins associated with alpha-synuclein . In …
… preclinical phase of Lewy body disease . Alpha-synuclein – Aggregated alpha-synuclein is a key component of Lewy bodies and Lewy neurites . Alpha-synuclein is expressed throughout the brain and is localized …
…MSA contain hyperphosphorylated alpha-synuclein, tau, ubiquitin, leucine-rich repeat serine/threonine-protein kinase 2, and many other proteins . Alpha-synuclein immunostaining is a sensitive marker of …
…one-third of the sleep cycle, most commonly affecting older adult males in association with alpha-synuclein neurodegenerative diseases including Parkinson disease, dementia with Lewy bodies, and multiple …
…These include: alpha-synuclein and other forms of neurodegeneration, orexin deficiency (narcolepsy), structural pontine lesions, and toxic effects from medications. Alpha-synuclein pathology, as seen in …
<掲載論文名> Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of α-synuclein neurotoxicity (前シナプス装置の足場およびレビー小体の構成成分であるSept4はα-シヌクレイン ...